Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + pertussis + hepatitis b + poliomyelitis vaccine
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to a combination vaccine developed by Sanofi Pasteur, typically known as a pentavalent or hexavalent vaccine (such as **Hexaxim** or **Hexyon** when including the Haemophilus influenzae type b component), which provides protection against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis. In the context of the provided clinical trial data (NCT04024358), this vaccine is used as a concomitant pediatric immunization in studies evaluating Sanofi's investigational quadrivalent meningococcal conjugate vaccine (**MenACYW-TT**; brand name **MenQuadfi**). The trial specifically assesses the safety and immunogenicity of MenACYW-TT when administered alongside this DTaP-HepB-IPV combination in infants and toddlers. The vaccine contains diphtheria and tetanus toxoids, acellular pertussis antigens, recombinant hepatitis B surface antigen, and inactivated poliovirus types 1, 2, and 3.
- Brand names
- HexaximHexyon
- Other names
- DTaP-HepB-IPV vaccineDTaP-IPV-HB
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)Poliovirus capsid proteinsHBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria + tetanus + pertussis + hepatitis b + poliomyelitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + pertussis + hepatitis b + poliomyelitis vaccine.